Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Partial Lipodystrophy: full-pipeline trial registry
2 of 3 indexed Partial Lipodystrophy trials are currently recruiting.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Partial Lipodystrophy: 3 US clinical trials tracked, 2 recruiting.
Partial Lipodystrophy is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Amryt Pharma, running 2 of these trials.
Enrollment posture brief
Registry condition partial-lipodystrophy
OPEN 2 | RECR 67% | LATE 1 | EARLY 1 | RANK #5209 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Partial Lipodystrophy lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Partial Lipodystrophy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Partial Lipodystrophy is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
MEASuRE: Metreleptin Effectiveness And Safety Registry
Amryt Pharma
NCT02325674
Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT05470504
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL
Amryt Pharma
NCT05164341
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Partial Lipodystrophy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Partial Lipodystrophy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Partial Lipodystrophy page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Partial Lipodystrophy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Amryt Pharma sponsors the most Partial Lipodystrophy trials on record, review their full trial history before evaluating a specific study. See Amryt Pharma's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Partial Lipodystrophy condition card totals 3 registered trials; most-linked intervention metreleptin; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.